Novanta (NOVT) Stock Could Be 11.3% Undervalued On Its Acquisition Growth Narrative

Recent Move in Novanta Stock

Novanta (NOVT) shares recently drew attention after a 2.6% gain in the latest session, contrasting with mixed returns over the past month and past 3 months and prompting a closer look at current fundamentals.

See our latest analysis for Novanta.

With the share price at $155.30, Novanta’s recent 2.6% one-day share price return comes after a softer 7-day share price return of 3.3%. However, the 90-day share price return of 32.3% and 1-year total shareholder return of 28.8% indicate momentum that has been building over a longer stretch despite some shorter-term pullbacks.

If you are weighing Novanta’s move alongside other opportunities in automation and precision technologies, this could be a good moment to broaden your search and check out 31 robotics and automation stocks

So with Novanta posting 6.5% annual revenue growth, 43.2% annual net income growth and trading around $155.30 against a $175.00 analyst target, is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 11.3% Undervalued

At a last close of $155.30 versus a narrative fair value of $175.00, Novanta is framed as undervalued, with that gap hinging on execution of an acquisition heavy growth plan.

The company's active pipeline of acquisitions, supported by a robust balance sheet and increased credit facility, is allowing it to continually enter new high growth, niche markets and increase its share of recurring, software-driven revenue, catalyzing long term revenue growth and reducing earnings volatility.

Read the complete narrative.

Want to understand why recurring medical consumables, higher margins and a richer earnings mix sit at the core of this fair value story? The key assumptions tie projected revenue growth, expanding profitability and a premium future earnings multiple together in a way that could reshape how you think about Novanta’s long term earnings power.

Result: Fair Value of $175 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Novanta story also leans on continued acquisition execution and assumes trade and tariff headwinds do not intensify enough to unsettle margins or growth expectations.

Find out about the key risks to this Novanta narrative.

Another View on Novanta’s Valuation

While the narrative fair value suggests Novanta is undervalued, the current P/E of 103x tells a very different story. It is far higher than the US Electronic industry at 32.9x and the 49.5x fair ratio. This points to richer expectations and a narrower margin for error. Which signal do you trust more?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Seen enough to sense both excitement and caution around Novanta, but still on the fence? Act while the information is fresh and weigh both sides with the 1 key reward and 1 important warning sign.

Looking For More Investment Ideas Beyond Novanta?

Before you move on, lock in what you have learned about Novanta and then widen your lens; the right comparison set can often change your conclusions.

• Target fresh opportunities in companies the market may be overlooking by scanning screener containing 19 high quality undiscovered gems that pair strong fundamentals with quieter investor attention.
• Strengthen the core of your portfolio by focusing on companies with sound finances using the solid balance sheet and fundamentals stocks screener (48 results) built for balance sheet resilience.
• Balance potential returns with a focus on stability by reviewing 66 resilient stocks with low risk scores that rank well on Simply Wall Street's risk scoring.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com